Literature DB >> 11687055

Transcutaneous electrical nerve stimulation (TENS) for chronic pain.

D Carroll1, R A Moore, H J McQuay, F Fairman, M Tramèr, G Leijon.   

Abstract

BACKGROUND: Transcutaneous electrical nerve stimulation (TENS) is used in a variety of different clinical settings to treat a range of different acute and chronic pain conditions and has become popular with both patients and health professionals.
OBJECTIVES: To evaluate the effectiveness of TENS in chronic pain. SEARCH STRATEGY: The Cochrane Library, Embase, Medline, CINAHL and The Oxford Pain Database were searched. Reference lists from retrieved reports and reviews were examined. Date of the most recent search: March 1999. SELECTION CRITERIA: RCTs were eligible if they included the following treatment comparisons: active TENS versus sham TENS controls active TENS versus no treatment controls active TENS versus active TENS controls (for instance High Frequency TENS vs Low Frequency TENS) Studies of patients suffering chronic pain for three months or more which included subjective outcome measures for pain intensity, or pain relief were eligible for evaluation in this review. No restrictions were made to language or sample size. Data from abstracts, letters, or unpublished studies, and studies of TENS in angina, headache and migraine, and dysmenorrhoea were not included. DATA COLLECTION AND ANALYSIS: Data were extracted and summarised on the following items: patients and details of pain condition, study treatments, study duration, design, methods, subjective pain outcome measures, methodological quality, results for pain outcome measures and adverse effects, and the conclusions made by the authors of the original studies. Extracted data and methodological quality of each report was confirmed by at least three of the reviewers. MAIN
RESULTS: Of 107 reports identified from the searches, 88 were excluded as they did not fulfil the pre-defined entry criteria. Nineteen RCTs (from 18 reports) were evaluated. The included trials varied in terms of design, analgesic outcomes, chronic pain conditions, TENS treatments and overall methodological quality. Studies included single and multiple dose treatment comparisons of TENS. The studies were small. The reporting of the methods used and results for the analgesic outcomes were generally poor. TENS treatments and controls were often poorly defined. Few studies evaluated the long-term analgesic effectiveness of TENS and single dose evaluations of TENS are unhelpful in making clinical decisions of the long-term effectiveness of TENS in the management of chronic pain. Meta-analysis was not possible. Overall in 10 of 15 inactive control studies there was a positive analgesic outcome in favour of the active TENS treatments. For the multiple dose treatment comparison studies only three of seven were considered to be in favour of the active TENS treatments. For the active controlled studies, seven studies made direct comparisons between HFTENS and LFTENS. Five of seven studies could find no difference in terms of analgesic efficacy between HFTENS and LFTENS at any time point. REVIEWER'S
CONCLUSIONS: The results of this review are inconclusive; the published trials do not provide information on the stimulation parameters which are most likely to provide optimum pain relief, nor do they answer questions about long-term effectiveness. Large multi-centre randomised controlled trials of TENS in chronic pain are urgently needed.

Entities:  

Mesh:

Year:  2001        PMID: 11687055     DOI: 10.1002/14651858.CD003222

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  24 in total

1.  BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation.

Authors:  T Kraus; K Hösl; O Kiess; A Schanze; J Kornhuber; C Forster
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

2.  Physiotherapy and low back pain in the injured worker: an examination of current practice during the subacute phase of healing.

Authors:  Katherine Harman; Anne Fenety; Alison Hoens; James Crouse; Bev Padfield
Journal:  Physiother Can       Date:  2009-05-12       Impact factor: 1.037

Review 3.  Effective treatments for pain in the older patient.

Authors:  Paul J Christo; Sean Li; Stephen J Gibson; Perry Fine; Haroon Hameed
Journal:  Curr Pain Headache Rep       Date:  2011-02

4.  Spinal 5-HT(2) and 5-HT(3) receptors mediate low, but not high, frequency TENS-induced antihyperalgesia in rats.

Authors:  Rajan Radhakrishnan; Ellen W King; Janelle K Dickman; Carli A Herold; Natalie F Johnston; Megan L Spurgin; Kathleen A Sluka
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

5.  Action potential simulation (APS) in patients with fibromyalgia syndrome (FMS): a controlled single subject experimental design.

Authors:  R K B Fengler; J W G Jacobs; M Bac; A J M van Wijck; N L U van Meeteren
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

Review 6.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Spinal cord stimulation for neuropathic pain: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

Review 8.  Minimising wound-related pain at dressing change: evidence-informed practice.

Authors:  Kevin Y Woo; Keith Harding; Patricia Price; Gary Sibbald
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

Review 9.  Transcutaneous electrostimulation for osteoarthritis of the knee.

Authors:  Anne Ws Rutjes; Eveline Nüesch; Rebekka Sterchi; Leonid Kalichman; Erik Hendriks; Manathip Osiri; Lucie Brosseau; Stephan Reichenbach; Peter Jüni
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

10.  The use of conventional transcutaneous electrical nerve stimulation in chronic facial myalgia patients.

Authors:  Ilaria De Giorgi; Tommaso Castroflorio; Barbara Sartoris; Andrea Deregibus
Journal:  Clin Oral Investig       Date:  2016-03-22       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.